Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
Post Views: 229 Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Health Sciences Authority (HSA) of Singapore has approved Trodelvy®(sacituzumab govitecan or SG) for the treatment of adult patients with unresectable…
